Breakout Stocks 




Biotech – Cancer Therapies

Presenting Thursday Dec 9,  2:30 PM

Register Here

Mr. Hoffman CEO will deliver his corporate presentation on Thursday, December 9, 2021 at 2:50 p.m. EST.


After hitting a yearly high of $3.35 earlier this year , these shares have consolidated to present levels where a solid base has been formed. We feel that these shares have been oversold and are ready to spring back to life . A new management team is now in place and a stronger company is about to evolve . These shares have just begun its rebound and a close above $0.75 cents will place these shares into BREAKOUT TERRITORY . Minor resistance exists at $1.00 and $1.50

Serious investors must place these shares immediately on their BUY LIST

Contact: Gary Zwetchkenbaum  Plum Tree Consulting LLC – Cell (516)455-7662 – Website: www.plumtreeconsultingllc.com


Kintara Therapeutics to Present at the MedInvest Oncology Investor Conference on December 9, 2021

SAN DIEGO , Dec. 7, 2021 /PRNewswire/ — Kintara Therapeutics, Inc . (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Chief Executive Officer, Robert E. Hoffman , will present a corporate overview at the MedInvest Oncology Investor Conference, which is being held virtually on December 7 – 10, 2021.

Mr. Hoffman will deliver his corporate presentation on Thursday, December 9, 2021 at 2:50 p.m. EST.

Mr. Hoffman will be available for one-on-one meetings throughout the conference.

Register for the conference:

Located in San Diego, California , Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs.  The two programs are VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).

VAL-083 is a “first-in-class”, small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara’s internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting its GBM AGILE study to support the development and commercialization of VAL-083 in GBM.

Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera Facebook and Linkedin .

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company’s clinical trials and the GBM AGILE study.  Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.  The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company’s operations and clinical trials; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.  These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended June 30, 2021 , the Company’s Quarterly Reports on Form 10-Q, and the Company’s Current Reports on Form 8-K.

More Info Contact

Gary Zwetchkenbaum  Plum Tree Consulting LLC – Cell (516)455-7662 – Website: www.plumtreeconsultingllc.com

Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision. We have not been paid for this article